New research from the USA suggests that popular acid reflux medications like Omeprazole, commonly used by many in the UK, could potentially trigger migraines. A study by American scientists revealed a higher likelihood of experiencing severe headaches among individuals who regularly consume acid-reducing drugs compared to those who do not.
These medications, including proton pump inhibitors (PPIs) like omeprazole and esomeprazole, histamine H2-receptor antagonists such as cimetidine and famotidine, and antacid supplements, are commonly taken to manage acid reflux, a condition where stomach acid flows back into the esophagus, typically after eating or lying down.
Individuals with acid reflux may experience symptoms like heartburn and ulcers, and persistent acid reflux could progress to gastroesophageal reflux disease (GERD), potentially leading to esophageal cancer. Professor Margaret Slavin from the University of Maryland, the lead author of the study, emphasized the need for further investigation into the potential link between acid-reducing drugs and migraines, especially considering the widespread use of these medications and their associated risks, such as an increased dementia risk from prolonged use of proton pump inhibitors.
The research team analyzed data from over 11,800 participants who reported their use of prescribed acid-reducing medications and their history of migraines or severe headaches in the preceding three months. The study revealed that a higher percentage of individuals taking PPIs, H2 blockers, and antacid supplements experienced severe headaches compared to those not using these drugs, even after adjusting for factors like age, gender, caffeine, and alcohol consumption.
According to the findings published in the journal Neurology Clinical Practice, individuals taking PPIs were 70% more likely to have migraines, while those using H2 blockers and antacid supplements had a 40% and 30% increased likelihood, respectively. Professor Slavin advised individuals with acid reflux or other conditions requiring acid-reducing medications to consult their healthcare providers regarding the continuation of these treatments if they experience migraines or severe headaches.
Although previous studies have indicated a potential association between gastrointestinal issues and migraines, Professor Slavin noted that this relationship alone may not fully explain the observed connection between acid-reducing drugs and migraines in this latest study.
At Reach and across our entities we and our partners use information collected through cookies and other identifiers from your device to improve experience on our site, analyse how it is used and to show personalised advertising. You can opt out of the sale or sharing of your data, at any time clicking the “Do Not Sell or Share my Data” button at the bottom of the webpage. Please note that your preferences are browser specific. Use of our website and any of our services represents your acceptance of the use of cookies and consent to the practices described in our Privacy Notice and Terms and Conditions.
